These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15997480)

  • 21. An interaction between S*tag and S*protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery.
    Asai T; Wims LA; Morrison SL
    J Immunol Methods; 2005 Apr; 299(1-2):63-76. PubMed ID: 15914191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene-directed enzyme prodrug therapy: a current assessment.
    McKeown SR; Ward C; Robson T
    Curr Opin Mol Ther; 2004 Aug; 6(4):421-35. PubMed ID: 15468601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colloidal gold modified with a genetically engineered nitroreductase: toward a novel enzyme delivery system for cancer prodrug therapy.
    Gwenin VV; Gwenin CD; Kalaji M
    Langmuir; 2011 Dec; 27(23):14300-7. PubMed ID: 22014024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.
    Fang L; Sun D
    Drug Metab Dispos; 2008 Jun; 36(6):1153-65. PubMed ID: 18356268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction and optimization of a CC49-based scFv-beta-lactamase fusion protein for ADEPT.
    Roberge M; Estabrook M; Basler J; Chin R; Gualfetti P; Liu A; Wong SB; Rashid MH; Graycar T; Babé L; Schellenberger V
    Protein Eng Des Sel; 2006 Apr; 19(4):141-5. PubMed ID: 16436454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-enzyme fusion proteins for cancer therapy.
    Andrady C; Sharma SK; Chester KA
    Immunotherapy; 2011 Feb; 3(2):193-211. PubMed ID: 21322759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT).
    Varner JD
    Syst Biol (Stevenage); 2005 Dec; 152(4):291-302. PubMed ID: 16986273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.
    Greco O; Dachs GU
    J Cell Physiol; 2001 Apr; 187(1):22-36. PubMed ID: 11241346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.
    Nishi Y
    Curr Pharm Des; 2003; 9(26):2113-30. PubMed ID: 14529409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted monoclonal antibody-based treatment of hematological malignancies.
    Kaspers GJ
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):253-5. PubMed ID: 12820769
    [No Abstract]   [Full Text] [Related]  

  • 33. Antibody-directed enzyme/prodrug therapy (ADEPT).
    Bagshawe KD
    Biochem Soc Trans; 1990 Oct; 18(5):750-2. PubMed ID: 2083666
    [No Abstract]   [Full Text] [Related]  

  • 34. [Targeting of antitumor drugs with monoclonal antibodies].
    Monneret C; Florent JC
    Bull Cancer; 2000 Nov; 87(11):829-38. PubMed ID: 11125291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Image-guided enzyme/prodrug cancer therapy.
    Li C; Penet MF; Winnard P; Artemov D; Bhujwalla ZM
    Clin Cancer Res; 2008 Jan; 14(2):515-22. PubMed ID: 18223227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-directed enzyme prodrug therapy.
    Bagshawe KD
    Clin Pharmacokinet; 1994 Nov; 27(5):368-76. PubMed ID: 7851054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates.
    Gesson JP; Jacquesy JC; Mondon M; Petit P; Renoux B; Andrianomenjanahary S; Dufat-Trinh Van H; Koch M; Michel S; Tillequin F
    Anticancer Drug Des; 1994 Oct; 9(5):409-23. PubMed ID: 7945725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.
    Kaliberov SA; Chiz S; Kaliberova LN; Krendelchtchikova V; Della Manna D; Zhou T; Buchsbaum DJ
    Cancer Gene Ther; 2006 Feb; 13(2):203-14. PubMed ID: 16082379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment.
    Loisel S; Ohresser M; Pallardy M; Daydé D; Berthou C; Cartron G; Watier H
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):34-42. PubMed ID: 17197192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody targeted drugs as cancer therapeutics.
    Schrama D; Reisfeld RA; Becker JC
    Nat Rev Drug Discov; 2006 Feb; 5(2):147-59. PubMed ID: 16424916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.